Compare LyondellBasell Industries NV (LYB) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs TransMedics Group Inc — how do they compare? LyondellBasell Industries NV trades at $60.67 (market cap $19.49B), while TransMedics Group Inc trades at $77.72 (market cap $2.74B). The key difference: LyondellBasell Industries NV is far larger — about 7.1× TransMedics Group Inc's market cap, and LyondellBasell Industries NV pays a 4.57% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold LyondellBasell Industries NV for 87 Days and TransMedics Group Inc for 24 Days on average.
| LYB | TMDX | |
|---|---|---|
Market Cap | $19.49B | $2.74B |
Volume | 6,033,396 | 949,331 |
Sector | Basic Materials | Health |
52-Week High | $82.38 | $150.42 |
52-Week Low | $42.28 | $61.99 |
Typical Hold Time | 87 Days | 24 Days |
Enterprise Value | $31.08B | $3.13B |
Dividend Yield | 4.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LYB trades at $60.90, up 4.12% today, with a bearish technical signal and mixed fundamentals. Revenue declined to $30.15B in 2025, with a net loss of $745M, though recent quarters show earnings beats. The stock is near its 52-week low, with key support at $60. Analyst consensus is split evenly between Buy and Hold, with a $69.38 price target. Recent news highlights dividend sustainability concerns amid chemical sector volatility.
Outlook remains cautious due to profitability challenges and high debt, but operational improvements and a 45% analyst buy rating suggest recovery potential. Risks include cyclical demand, margin pressure, and dividend coverage issues. The stock offers value at current levels if earnings stabilize, but investors should monitor cash flow trends and sector headwinds.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
